MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Travere Therapeutics Inc

Suletud

17.45 -2.13

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.33

Max

18.84

Põhinäitajad

By Trading Economics

Sissetulek

-5.5M

-60M

Müük

12M

75M

Aktsiakasum

-0.47

Kasumimarginaal

-80.586

Töötajad

385

EBITDA

-4.6M

-45M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+89.73% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-138M

1.7B

Eelmine avamishind

19.58

Eelmine sulgemishind

17.45

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Travere Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. veebr 2025, 13:58 UTC

Suurimad hinnamuutused turgudel

Travere to Seek FDA OK of Filspari in Rare Kidney Disorder FSGS; Shares Rally

Võrdlus sarnastega

Hinnamuutus

Travere Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

89.73% tõus

12 kuu keskmine prognoos

Keskmine 34 USD  89.73%

Kõrge 47 USD

Madal 22 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Travere Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

13

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 20.98Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.